If someone has Alzheimer's, you can write a check for any amount and nobody knows how to cure it
Em algum ponto entre a ambição científica e a mortalidade humana, uma startup californiana chamada Retro Biosciences decidiu tratar o envelhecimento não como destino, mas como doença tratável. Apoiada por $180 milhões do CEO da OpenAI, Sam Altman — quase a totalidade de seu patrimônio pessoal —, a empresa busca agora $1 bilhão em capital para avançar uma pipeline de vinte medicamentos que prometem reverter o relógio biológico. A aposta não é apenas financeira: é uma reconfiguração do que a medicina considera possível.
- Retro Biosciences quer estender a vida humana em dez anos não tratando doenças do envelhecimento, mas revertendo o próprio processo biológico que as causa.
- Seu primeiro medicamento, RTR242, já mira o Alzheimer reativando a autofagia celular — mas nenhuma terapia da empresa chegou ainda a ensaios clínicos, o que torna a avaliação de $5 bilhões controversa.
- A empresa projeta superar Eli Lilly e Novo Nordisk em valor de mercado, comparando seu potencial ao da Microsoft ou Alphabet, em um mercado que consome mais de $3 trilhões anuais só nos EUA.
- Com vinte medicamentos em desenvolvimento, parceria com a OpenAI para engenharia de proteínas via IA e um novo membro no conselho coordenando o aporte, a Retro acelera sua corrida por capital e credibilidade científica.
Sam Altman apostou quase todo o seu patrimônio pessoal em duas empresas: a Helion, de fusão nuclear, e a Retro Biosciences, uma startup californiana fundada há cinco anos com uma missão radical — reverter o envelhecimento humano e estender a vida em uma década. Seu investimento inicial de $180 milhões, um dos maiores aportes seed já registrados, vale hoje $258 milhões.
A estratégia da Retro não é tratar as doenças que acompanham a velhice, mas atacar o mecanismo subjacente. A empresa combina edição epigenética — alterando os interruptores moleculares que regulam genes — com terapias de substituição celular, buscando regenerar tecidos deteriorados a partir de dentro. O CEO Joe Betts-LaCroix descreve um cenário em que um paciente de 85 anos submetido à terapia de células-tronco sanguíneas poderia ter 80% de suas células rejuvenescidas para a idade zero.
O primeiro candidato clínico, RTR242, mira o Alzheimer reativando a autofagia, o processo de reciclagem celular que se desregula com a idade. Mas a pipeline vai além: são cerca de vinte medicamentos em desenvolvimento, incluindo terapias que substituem micróglias cerebrais e células-tronco do sangue envelhecidas. A empresa também colabora com a OpenAI no desenvolvimento de um modelo de IA especializado em engenharia de proteínas.
Agora a Retro busca $1 bilhão a uma avaliação de $5 bilhões — cifra que gerou ceticismo, dado que nenhuma terapia chegou ainda a ensaios clínicos. Ainda assim, o argumento de mercado é difícil de ignorar: doenças ligadas ao envelhecimento respondem por cerca de 90% dos gastos com saúde nos EUA, mais de $3 trilhões ao ano. Os fundadores projetam que a longevidade será o maior mercado farmacêutico da história, com potencial para rivalizar com gigantes como Microsoft e Alphabet em valor. O que determina se essa visão se concretiza é, no fim, a velocidade da ciência.
Sam Altman has bet his personal fortune on a radical proposition: that aging itself can be stopped, and then reversed. The OpenAI chief executive placed $180 million into Retro Biosciences, a California biotech startup founded five years ago, in what ranks among the largest seed investments ever made. His stake is now worth $258 million. But Altman is not content to be a passive investor. He has committed nearly his entire net worth to two companies—Retro and the nuclear fusion energy firm Helion—betting that both will reshape how humans live.
Retro's ambition is plainly stated: extend human lifespan by a decade by reversing the aging process itself. Rather than treating the diseases that accumulate with age—Alzheimer's, heart disease, cancer, hearing loss—the company proposes to halt and reverse the biological clock. The strategy combines multiple approaches. One involves altering epigenetic mechanisms, the cellular switches that turn genes on and off. Another replaces worn or damaged cells with fresh ones. The goal is to coax the body into producing healthier cells within tissues that have begun to deteriorate.
The first drug to enter human testing is RTR242, designed to combat Alzheimer's by reactivating autophagy, the cellular recycling process that typically becomes dysregulated in aging. But the company's ambitions extend far beyond a single disease. Its pipeline contains roughly twenty drugs in development, targeting everything from blood disorders to hearing loss to neurodegenerative disease. Some of these are cellular therapies—one replaces the brain cells called microglia that defend the central nervous system; another swaps aging blood stem cells for younger ones. According to CEO Joe Betts-LaCroix, a patient of eighty-five undergoing this blood therapy could see eighty percent of their cells become age zero, multiplying indefinitely.
Now Retro is hunting for capital. The company has been seeking $1 billion at a $5 billion valuation since early in the year, according to the Financial Times. The figure struck many observers as aggressive—none of Retro's therapies have yet entered clinical trials. But the company's pitch deck paints a staggering picture. Retro's founders project that their company will eventually surpass pharmaceutical giants like Eli Lilly and Novo Nordisk in market value, reaching valuations comparable to Microsoft or Alphabet. "Longevity will be the largest pharmaceutical market of all time," one slide declares.
The math is not difficult to follow. In the United States alone, diseases tied to aging consume roughly ninety percent of all healthcare spending—more than $3 trillion annually. The final months of a person's life typically represent the costliest period for both public and private health systems. Globally, the pattern repeats. This is not a niche market. It is the entire structure of modern medicine.
Retro's founding team brings credible scientific pedigree. Betts-LaCroix, the CEO, has launched other technology startups, including an AI platform for laboratory research. Sheng Ding is internationally recognized for work in stem cells and cellular reprogramming. Matt Buckley specializes in the mechanisms of aging itself. When Betts-LaCroix speaks about the company's mission, he frames it in terms of human suffering. "Right now, if someone has Alzheimer's, you can write a check for any amount and nobody knows how to cure it," he told the Financial Times. The company also maintains a partnership with OpenAI to develop GPT-4b micro, a specialized AI model for protein engineering.
Sandro Salsano, an Italian investor with a family office based in Panama, recently joined Retro's board and is coordinating the fundraising round. The valuation and the aggressive timeline have drawn skepticism from some quarters. But the fundamental bet—that aging is a solvable problem, that the market for solutions is enormous, and that the science is moving fast enough to justify the price—has attracted serious money and serious attention. What happens next depends on whether the science can deliver on the promise.
Citas Notables
Longevity will be the largest pharmaceutical market of all time— Retro Biosciences pitch deck
I basically took all my net worth and invested it in two companies— Sam Altman, on Retro and Helion Energy
La Conversación del Hearth Otra perspectiva de la historia
Why does Sam Altman believe aging is a problem that can be solved? What makes him confident enough to put his entire net worth on it?
He's not betting on a cure for one disease. He's betting that aging itself is the disease—that if you can slow or reverse the biological clock, you solve dozens of problems at once. The science of cellular reprogramming and epigenetics has moved fast enough that it no longer sounds like science fiction.
But the company has no drugs in human trials yet. How does a $5 billion valuation make sense?
It doesn't, if you're valuing it like a traditional pharma company. But Retro is being valued on the size of the market it could capture. If aging-related diseases cost the U.S. healthcare system $3 trillion a year, and you have a therapy that actually works, the addressable market is almost unlimited.
The pitch deck says Retro could become bigger than Microsoft. That seems like fantasy.
It does. But consider: if they succeed even partially, they're not just selling a drug. They're selling decades of additional life. The willingness to pay for that is not constrained by normal pharmaceutical pricing. It's constrained only by wealth itself.
What's the actual scientific claim here? Can you really reverse aging?
They're not claiming to reverse it completely—not yet. The first drug targets Alzheimer's by restarting cellular recycling. Other therapies replace old cells with young ones. It's incremental. But the theory is sound: aging is a process, and processes can be interrupted.
Who's actually running this? Are these credible scientists?
The CEO has built tech startups before. One founder is a recognized expert in stem cells and reprogramming. Another specializes in aging biology. They're not fringe figures. And they have OpenAI's resources behind them—they're using AI to design proteins. That's real infrastructure.
What happens if they fail?
Then Altman loses his fortune, and the field learns something about what doesn't work. But if they succeed even partially, they reshape medicine entirely. That's why the bet is worth making.